FLYRCADO Approval Signals Tighter GMP Scrutiny for F-18 Radiopharmaceuticals

GE Healthcare's September 2024 FDA approval of FLYRCADO (Flurpiridaz F 18 Injection) places renewed operational pressure on nuclear pharmacy manufacturers and contract sites handling short-lived F-18 labeled compounds, where GMP compliance windows are compressed by radioactive decay and real-time release requirements that standard small-molecule frameworks do not anticipate.

FLYRCADO is indicated for myocardial perfusion imaging via PET in adult patients with known or suspected coronary artery disease. The product is administered intravenously, typically as two sequential doses: one at rest and one under pharmacologic or exercise stress. PET imaging is performed after each dose to identify regions of reduced myocardial blood supply. The clinical package supporting approval drew on two prospective, multicenter, open-label trials enrolling 1,333 evaluable patients across 48 and 76 sites respectively, spanning the United States, Canada, Finland, France, Germany, and the Netherlands. Safety data covered 1,600 patients who received one or two doses.

For QA directors and plant heads operating within nuclear pharmacy or radiopharmaceutical contract manufacturing, the approval underscores the need to align existing GMP infrastructure with the specific demands of F-18 production: accelerator-dependent synthesis, sub-two-hour half-life logistics, and blinded reader protocols that mirror the diagnostic rigor regulators now expect at the clinical evidence level. Trial imaging reads were performed by three independent, blinded qualified readers who assessed overall perfusion diagnoses against invasive coronary angiography as the reference standard, a methodological bar that informs how post-market quality systems must document product performance traceability.

Source: FDA Drug Trials Snapshots, FLYRCADO, approved September 27, 2024. Published April 29, 2026. GE Healthcare Inc. Trials: NCT03354273 and NCT01347710.